Unpublished documents

WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization

SAGE_eYB_Sept2023.pdf (who.int)

https://theconversation.com/malaria-two-groundbreaking-vaccines-have-been-developed-but-access-and-rollout-are-still-big-stumbling-blocks-217146?

Dabira, D., 2023. Towards malaria elimination: innovative tools and interventions to accelerate interruption of malaria transmission in The Gambia (Doctoral dissertation, University of Antwerp). https://repository.uantwerpen.be/desktop/irua

Published documents

Thomson-Luque, R., Stabler, T.C., Fürle, K., Silva, J.C. and Daubenberger, C., 2024. Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate. Expert Review of Vaccines, 23(1), pp.160-173. https://doi.org/10.1080/14760584.2023.2295430

Isabella, O.A., Ann, O., Oyeniyi, A.A., Ukamaka, O. and Okechi, N., Unlocking the Future: Predicting Malaria Vaccine Uptake and Likely Barriers in Nigeria. (NOT OA)

Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Orindi B, Ramos Lopez F, Flaxman A, Cappuccini F, Kailath R, Elias S, Mukhopadhyay E, Noe A, Cairns M, Lawrie A, Roberts R, Valéa I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021 May 15;397(10287):: 10.1016/S0140-6736(21)00943-0.

Genton, B., 2023. R21/Matrix-M™ malaria vaccine: a new tool to achieve WHOs goal to eliminate malaria in 30 countries by 2030?. Journal of Travel Medicine, p.taad140. https://doi.org/10.1093/jtm/taad140

Ajayi, M.Y. and Emeto, D.C., 2023. Awareness and acceptability of malaria vaccine among caregivers of under-5 children in Northern Nigeria. Malaria Journal, 22(1), p.329. DOI: 10.1186/s12936-023-04768-z

Dzi, K.T., 2023. Before we get excited about the approval of the R21/Matrix-M malaria vaccine for use in Nigeria and Ghana, let’s review the issues. Frontiers in Public Health, 11, p.1237011. DOI: 10.3389/fpubh.2023.1237011

Siddiqui, A.J., Bhardwaj, J., Saxena, J., Jahan, S., Snoussi, M., Bardakci, F., Badraoui, R. and Adnan, M., 2023. A critical review on human malaria and schistosomiasis vaccines: current state, recent advancements, and developments. Vaccines, 11(4), p.792. DOI: 10.3390/vaccines11040792

Datoo, M.S., Natama, H.M., Somé, A., Bellamy, D., Traoré, O., Rouamba, T., Tahita, M.C., Ido, N.F.A., Yameogo, P., Valia, D. and Millogo, A., 2022. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. The Lancet Infectious Diseases, 22(12), pp.1728-1736. DOI: 10.1016/S1473-3099(22)00442-X

Daubenberger, C.A. and Moncunill, G., 2022. Next-generation malaria subunit vaccines to reduce disease burden in African children. The Lancet Infectious Diseases, 22(12), pp.1655-1656. (NOT OA)

Collins, K.A., Brod, F., Snaith, R., Ulaszewska, M., Longley, R.J., Salman, A.M., Gilbert, S.C., Spencer, A.J., Franco, D., Ballou, W.R. and Hill, A.V., 2021. Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. Scientific Reports, 11(1), p.10792. DOI:https://doi.org/10.1016/S1473-3099(22)00523-0

Parums, D.V., 2022. Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 28, pp.e939357- doi: 10.12659/MSM.939357